Opinion|Videos|July 12, 2024
AGAVE-201 Trial Review
A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Please provide an overview of the AGAVE-201 trial, including its design, patient population, and key endpoints.
- What were the primary and secondary endpoints of the AGAVE-201 trial, and how were they assessed?
- How did the trial evaluate the efficacy, safety, and tolerability of different dosing regimens of axatilimab in patients with recurrent or refractory active chronic GVHD?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5